Centrum 7/6  banner

Aurobindo gets FDA approval for lacosamide oral solution

Print Friendly, PDF & Email

EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application lacosamide oral solution USP, 10mg/mLs. Aurobindo Pharma’s lacosamide oral solution, are an AB-rated generic equivalent to the reference listed drug (RLD),  VIMPAT Oral Solution manufactured by UCB.

Lacosamide oral solution are indicated in patients 17 years and older with partial-onset seizures as monotherapy or adjunctive therapy.

Lacosamide oral solution has an estimated market size of US $70.4 Million for the twelve months ending Nov 2023, as per IQVIA.


ECRM_06-01-22


Comments are closed.

PP_1170x120_10-25-21